Johnson & Johnson Operating Expenses 2010-2024 | JNJ

Johnson & Johnson annual/quarterly operating expenses history and growth rate from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
  • Johnson & Johnson operating expenses for the quarter ending September 30, 2024 were $19.133B, a 18.59% increase year-over-year.
  • Johnson & Johnson operating expenses for the twelve months ending September 30, 2024 were $70.070B, a 10.19% increase year-over-year.
  • Johnson & Johnson annual operating expenses for 2023 were $70.097B, a 15.61% increase from 2022.
  • Johnson & Johnson annual operating expenses for 2022 were $60.631B, a 1.79% increase from 2021.
  • Johnson & Johnson annual operating expenses for 2021 were $59.562B, a 9.87% decline from 2020.
Johnson & Johnson Annual Operating Expenses
(Millions of US $)
2023 $70,097
2022 $60,631
2021 $59,562
2020 $66,087
2019 $64,731
2018 $63,582
2017 $58,777
2016 $52,087
2015 $50,878
2014 $53,768
2013 $55,841
2012 $53,449
2011 $52,669
2010 $44,640
2009 $46,142
Johnson & Johnson Quarterly Operating Expenses
(Millions of US $)
2024-09-30 $19,133
2024-06-30 $16,699
2024-03-31 $17,669
2023-12-31 $16,569
2023-09-30 $16,134
2023-06-30 $15,213
2023-03-31 $22,181
2022-12-31 $10,063
2022-09-30 $14,824
2022-06-30 $18,180
2022-03-31 $17,564
2021-12-31 $8,531
2021-09-30 $19,489
2021-06-30 $16,650
2021-03-31 $14,892
2020-12-31 $20,828
2020-09-30 $16,681
2020-06-30 $14,396
2020-03-31 $14,182
2019-12-31 $16,529
2019-09-30 $19,082
2019-06-30 $13,521
2019-03-31 $15,599
2018-12-31 $17,272
2018-09-30 $15,925
2018-06-30 $15,857
2018-03-31 $14,528
2017-12-31 $17,635
2017-09-30 $14,860
2017-06-30 $14,091
2017-03-31 $12,191
2016-12-31 $13,782
2016-09-30 $12,539
2016-06-30 $13,578
2016-03-31 $12,188
2015-12-31 $14,053
2015-09-30 $12,980
2015-06-30 $12,046
2015-03-31 $11,799
2014-12-31 $15,551
2014-09-30 $11,657
2014-06-30 $13,869
2014-03-31 $12,691
2013-12-31 $15,605
2013-09-30 $13,908
2013-06-30 $13,084
2013-03-31 $13,244
2012-12-31 $14,458
2012-09-30 $13,457
2012-06-30 $14,440
2012-03-31 $11,094
2011-12-31 $15,937
2011-09-30 $11,894
2011-06-30 $13,175
2011-03-31 $11,663
2010-12-31 $13,416
2010-09-30 $10,763
2010-06-30 $11,110
2010-03-31 $9,351
2009-12-31 $13,947
2009-09-30 $10,836
2009-06-30 $10,976
2009-03-31 $10,383
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $368.366B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94